APrevent Medical Inc. Secures $6 Million in Series D Funding Led by Taiwania Capital

From Left to Right: Chief Financial Officer of Aprevent, Jia-Yang (Kevin) Chiu; Chief Operating Officer and Chief Technology Officer of Aprevent, Mark Chang; Co-Funder and Chief Executive Officer of Aprevent, Guan-Min Ho; Chief Executive Officer of Taiwania Capital, David Weng; General Partner of Bio Fund of Taiwania Capital, Jerome Shen, Ph.D.; Managing Partner of CEE Fund of Taiwania Capital, Mitch Yang.

APrevent Medical Inc. (APrevent), a leader in vocal health technology, is thrilled to announce the successful closing of a $6 million Series D funding round led by Taiwania Capital, a leading venture capital firm in Taiwan , backed by Taiwan’s public and private sectors which focus on investing in innovative companies in High-tech and Biotech fields.


This significant funding injection represents a pivotal moment for APrevent as it advances its mission to revolutionize vocal health care. With a focus on pioneering solutions, APrevent is renowned for its flagship product, the APrevent® VOIS VOCAL IMPLANT SYSTEM, designed with a unique blend of silicone and titanium, two inert and hypoallergenic materials.


The APrevent® VOIS distinguishes itself with its innovative design, allowing for both intraoperative and postoperative adjustments, a breakthrough feature not found in other implants on the market. This versatility enables optimized results while significantly reducing complications and revision rates. Follow-up procedures are streamlined, and postoperative implant adjustments ensure individualized optimization without the need for revision surgery.


“We are thrilled to have Taiwania Capital lead our Series D funding round as we continue to drive innovation in vocal health technology,” said Dr. Ho, Guan-Min, CEO of APrevent. “This investment underscores the confidence in our mission and the potential of the APrevent® VOIS to revolutionize patient care worldwide.”


The biocompatible medical-grade silicone and titanium materials of the APrevent® VOIS, combined with its precise design, offer numerous benefits, including improved voice quality, enhanced swallowing function, and prevention of complications arising from glottic insufficiency. Additionally, its standardized implantation procedure reduces pain and shortens recovery time, ensuring a more comfortable experience for patients.


David Weng, CEO of Taiwania Capital, says ” Taiwania Capital is delighted to invest in such a promising medical device company. APrevent’s product is revolutionary in treating patients suffering from glottic insufficiency.”


“We believe that APrevent has the potential to make a significant impact on the field of vocal healthcare through its innovative solutions,” said Mitch Yang, Managing Partner of CEE Fund at Taiwania Capital. “We are excited to partner with APrevent. Taiwania Capital’s presence in the CEE region and our network in the medical device industry could play a pivotal role in the company’s further expansion into the European market.”

Read More